ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women’s health, has announced the acquisition of the scientific assets of Imagen Therapeutics Limited from its appointed liquidators for £170,000.
UK pharmaceutical services company Imagen offered personalised cancer treatment through the collection and use of well-characterised, patient-derived cells.
• Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio.
• Agreement to utilize PrecisionLife’s combinatorial analytics platform to identify genetic biomarkers that will optimize patient selection across multiple CNS clinical trials.
AMSBIO is a leading provider of ready-to-use Adeno-Associated Virus (AAV) that can be engineered to efficiently deliver specific DNA sequences into target cells with a low immunogenicity.
Aptamer Group CTO, Dr David Bunka, will present at Neuro-Bio’s Science Day on Optimer technology and the development of binders to support the diagnostic
From streamlining R&D workflows and collaboration with data-driven software platforms, to building tools that make the development of new therapies possible, to empowering more efficient and inclusive clinical trials, companies in the tech bio space are laying the foundations for a new era of life science and digital technology innovations.
Appointment supports growth of Metrion’s pre-clinical ion channel contract research and safety pharmacology services
Cambridge, UK, 12 June 2023: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Steve Jenkinson as Vice President, Drug Discovery and Safety Assessment. The US-based appointment represents an important step in the expansion of Metrion’s business, driven by its ion channel discovery capabilities.
Cambridge 12th June 2023: Babraham Research Campus Ltd (BRC), the organisation which oversees the development and day-to-day management of the Babraham Research Campus is delighted to welcome Charlie Foreman to the Board as non-executive director.
BioIVT, a leading provider of biospecimens and ADME-Tox research products and services for drug and diagnostic development, today announced that it will be showcasing its expanded ADME-Tox portfolio at the 16th European ISSX and DMDG Meeting, which will be held from June 11-14 at the University of Hertfordshire in the UK.